Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors

International Journal of Molecular Sciences - Switzerland
doi 10.3390/ijms20174235
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

MDPI AG

Related search

Combining Checkpoint Inhibitors and BRAF-targeted Agents Against Metastatic Melanoma

OncoImmunology
OncologyAllergyImmunology
2013English

1186 Fisetin Attenuates Melanoma Growth and Tumorigenicity by Downregulating PI3K/MAPK Signaling and Disrupting eIF4F Complex

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2018English

809 Pou4f1 Promotes Braf Inhibitor Resistance by Reactivating Mapk Signaling Pathway in Melanoma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Will PI3K Pathway Inhibitors Be Effective as Single Agents in Patients With Cancer?

Oncotarget
Oncology
2011English

Inhibitors of Pan-Pi3k Signaling Synergize With BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

Frontiers in Oncology
Cancer ResearchOncology
2015English

Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma

Cancer Discovery
Oncology
2019English

Combining BET and HDAC Inhibitors Synergistically Induces Apoptosis of Melanoma and Suppresses AKT and YAP Signaling

Oncotarget
Oncology
2015English

Correction: Will PI3K Pathway Inhibitors Be Effective as Single Agents in Patients With Cancer?

Oncotarget
Oncology
2018English

Lycorine Inhibits Melanoma A375 Cell Growth and Metastasis Through the Inactivation of the PI3K/AKT Signaling Pathway

Medecine/Sciences
BiochemistryMedicineGeneticsMolecular Biology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy